



FDA-AACR Workshop on  
**HOW MUCH IS ENOUGH?  
 TRIAL DESIGNS FOR TREATMENT  
 REGIMENS WITH MULTIPLE PHASES**

May 9, 2024, 9 a.m.–4 p.m. | Bethesda, MD

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients.

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark, C, Copyright; OIP, Other Intellectual Property; O, Other

| Last Name        | First Name | All Relationships   | Type   | Role    |
|------------------|------------|---|--|---------|
| Akinboro         | Oladimeji  | No Relationships  |  | Speaker |
| Amatya           | Anup       | No Relationships  |  | Speaker |
| Amiri-Kordestani | Laleh      | No Relationships  |  | Speaker |
| Anagnostou       | Valsamo    | AstraZeneca, Bristol-Myers Squibb, Delfi Diagnostics  | GC, GC, GC   | Speaker |
| Arthur           | Ronald     | No Relationships  |  | Staff   |
| Axelson          | Michael    | Eli Lilly and Company, Eli Lilly and Company  | E, S   | Speaker |
| Bhatnagar        | Vishal     | No Relationships  |  | Speaker |
| Brown            | Thelma     | No Relationships  |  | Speaker |
| DeClaro          | Angelo     | No Relationships  |  | Speaker |
| Forde            | Patrick    | Janssen Global Services, LLC, Merck, Regeneron Pharmaceuticals, LUNgevity Foundation, Flame Biosciences, AstraZeneca, F-Star, Novartis, G1 Therapeutics, BioNTech, SANOFI PASTEUR INC., Bristol-Myers Squibb, Novartis, Daiichi Sankyo Company, Genentech, Polaris, Surface Oncology, Bristol-Myers Squibb, AstraZeneca, Iteos, Amgen | IC, IC, GC, IC, IC, IC, IC, IC, IC, GC, IC, IC, GC, IC, IC, IC, IC, GC, GC, IC, IC | Speaker |
| Gause            | Christine  | Merck & Co., Inc., Merck & Co., Inc.  | E, S   | Speaker |
| George           | Manju      | Amgen, CRISPR Therapeutics AG, Johnson & Johnson Health Care Systems Inc., Natera, Pfizer   | S, S, S, S, S  | Speaker |



FDA-AACR Workshop on  
**HOW MUCH IS ENOUGH?  
 TRIAL DESIGNS FOR TREATMENT  
 REGIMENS WITH MULTIPLE PHASES**

May 9, 2024, 9 a.m.–4 p.m. | Bethesda, MD

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

| Last Name            | First Name | All Relationships   | Type   | Role                       |
|----------------------|------------|---|--|----------------------------|
| Giaccone             | Giuseppe   | Amgen Inc.  | E  | Speaker                    |
| Gormley              | Nicole     | No Relationships  |  | Speaker                    |
| Gray                 | Jhanelle   | Oncocyte, Inivata, Gilead Sciences Inc, Blueprint Medicines Corporation, Bristol Myers Squibb Company, AstraZeneca, G1 Therapeutics, Daiichi Sankyo Company, Pfizer, Axiom HC Strategies, Boehringer Ingelheim, Ludwig Institute of Cancer Research, Janssen Scientific Affairs, LLC, AbbVie, EMD Serono, Triptych Health Partners, Jazz Pharmaceuticals Inc., Merck, Novartis, Celgene Corporation, Moffitt Cancer Center, Loxo Oncology, Sanofi Pharmaceuticals, Takeda Pharmaceuticals   | IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, O, IC, IC, IC, IC, IC, IC, IC, IC, E, IC, IC, IC                                       | Speaker                    |
| Haddock Lobo Goulart | Bernardo   | No Relationships  |  | Speaker                    |
| Herbst               | Roy        | EMD Serrano, NextCure, Society for Immunotherapy of Cancer, Merck, Abbvie Pharmaceuticals, NextCure, Janssen Biotech, IMAB Biopharma, Ribon Therapeutics, Ocean Biomedical, Genentech/Roche, Checkpoint Therapeutics, Candel Therapeutics, AstraZeneca, American Association for Cancer Research, Seattle Genetics, Oncocyte, DynamiCure Biotechnology, Oncternal Therapeutics, Eli Lilly and Company, AstraZeneca, Cybrea Therapeutics, eFFECTOR Therapeutics, Junshi Pharmaceuticals, Xencor Inc, Regeneron Pharmaceuticals, Pfizer, Gilead Research Foundation, International Association for the Study of Lung Cancer, Immunocore, Normunity, Novartis, Loxo Oncology, Immune-Onc Therapeutics, Merck, Bolt Biotherapeutics, SANOFI PASTEUR INC., Mirati Therapeutics, Bristol-Myers Squibb, HiberCell, Eli Lilly and Company, Johnson & Johnson Health Care Systems Inc. | IC, IC, IC, GC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, GC, GC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC | Speaker                    |
| Hirsch               | Fred       | Amgen, SANOFI US SERVICES INC., Daiichi Sankyo Company, Icahn School of Medicine at Mount Sinai, Nectin Therapeutics, Novartis, Regeneron Pharmaceuticals, OncoCyte, Genentech, AstraZeneca, Bristol-Myers Squibb   | IC, IC, IC, E, IC, IC, IC, IC, IC, IC, IC  | Speaker                    |
| Horiba               | Naomi      | No Relationships  |  | Speaker                    |
| Jaffee               | Elizabeth  | Abmeta Therapeutics, Dragonfly Therapeutics, Adventris, Lustgarten Foundation, HDT Bio, Neuvogen, NeoTx, Mestag Therapeutics, CPRIT, Break Through Cancer, Orgenesis, Achilles Therapeutics, Parker Institute for Cancer Immunotherapy, Medically Home  | OBO, IC, OBO, IC, IC, IC, IC, IC, IC, IC, O, IC, IC, IC  | Program Committee, Speaker |



FDA-AACR Workshop on  
**HOW MUCH IS ENOUGH?  
 TRIAL DESIGNS FOR TREATMENT  
 REGIMENS WITH MULTIPLE PHASES**

May 9, 2024, 9 a.m.–4 p.m. | Bethesda, MD

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

| Last Name      | First Name | All Relationships   | Type  | Role    |
|----------------|------------|---|---|---------|
| Kidwell        | Kelley     | No Relationships  |   | Speaker |
| Kris           | Mark       | Bristol Myers Squibb Company, Sanofi Genzyme, Daiichi Sankyo, BerGenBio, Genentech, Merus, AstraZeneca, Mirati Therapeutics   | IC, IC, IC, IC, IC, IC, IC, IC  | Speaker |
| Larkins        | Erin       | No Relationships  |   | Speaker |
| Lemery         | Steven     | No Relationships  |   | Speaker |
| Migali         | Cristina   | No Relationships  |   | Speaker |
| Mishra-Kalyani | Pallavi    | No Relationships  |   | Speaker |
| Perlmutter     | Jane       | No Relationships  |   | Speaker |
| Powles         | Thomas     | Roche, F. Hoffmann-La Roche, Roche, Exelixis, Seattle Genetics, AstraZeneca, Novartis, Eisai, Pfizer, Merck, F. Hoffmann-La Roche, Seattle Genetics, Inc., Merck, Pfizer, Ipsen Biopharm Limited, Pfizer, MSD, Mashup Communications, Merck, F. Hoffmann-La Roche, Ipsen Biopharm Limited, F. Hoffmann-La Roche, F. Hoffmann-La Roche, Johnson & Johnson Health Care Systems Inc., Seattle Genetics, Inc., MSD, AstraZeneca, Gilead Sciences Inc, Gilead Sciences Inc, Queen Mary University of London, AstraZeneca, Bristol-Myers Squibb, Ipsen Biopharm Limited, Novartis, EMD Serono, Inc., Bristol-Myers Squibb, EMD Serono, Inc., MSD, Pfizer, Eisai, Hoffmann-La Roche Limited, Gilead Sciences Inc, Incyte Corporation, Johnson & Johnson Health Care Systems Inc., Pfizer, Mashup Communications, Genentech, Mashup Communications, Exelixis, Exelixis, Astellas Pharma, Novartis, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb | IC, IC, GC, GC, GC, IC, IC, IC, IC, IC, IC, GC, IC, IC, IC, GC, IC, GC, GC, IC, GC, IC, GC, IC, IC, IC, E, GC, IC, IC, GC, GC, IC, IC, IC, IC, GC, GC, IC, IC, GC, IC, IC, GC, IC, GC | Speaker |
| Prowell        | Tatiana    | No Relationships  |   | Speaker |
| Reuss          | Joshua     | Arcus Bioscience, Janssen Pharmaceuticals, AbbVie, Regeneron Pharmaceuticals, Gilead Sciences Inc, Exelixis, Seagen, Catalym, Daiichi Sankyo, Guardant Health, Summit Therapeutics, Genentech, AstraZeneca, Nuvalent, Novocure, Bristol-Myers Squibb  | IC, IC, IC, IC, IC, GC, IC, IC, IC, IC, IC, GC, IC, GC, IC, IC  | Speaker |
| Shah           | Mirat      | No Relationships  |   | Speaker |



FDA-AACR Workshop on  
**HOW MUCH IS ENOUGH?  
 TRIAL DESIGNS FOR TREATMENT  
 REGIMENS WITH MULTIPLE PHASES**

May 9, 2024, 9 a.m.–4 p.m. | Bethesda, MD

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

| Last Name  | First Name | All Relationships  | Type  | Role                       |
|------------|------------|--|---|----------------------------|
| Shan       | Minghua    | Moderna, Celldex Therapeutics, BeiGene, Ltd., Bayer, Intellia Therapeutics, Bayer  | S, S, S, S, S, E  | Speaker                    |
| Singh      | Harpeet    | No Relationships   |   | Program Committee, Speaker |
| Song       | Chi        | No Relationships   |   | Speaker                    |
| Sosa Mejia | Aaron      | No Relationships   |   | Speaker                    |
| Tendler    | Craig      | Janssen Research & Development, LLC  | E   | Speaker                    |
| Tolaney    | Sara       | Seattle Genetics, Mersana Therapeutics, Seattle Genetics, NanoString Technologies, Inc., CytomX Therapeutics, Genentech, Merck, SANOFI US SERVICES INC., Zentalis, Eli Lilly and Company, OncXerna, ARC Therapeutics, Myovant, Pfizer, Novartis Pharma, Zymeworks, Stemline Therapeutics Inc., Daiichi Sankyo Company, Merck, Gilead Sciences Inc, Cyclacel Pharmaceuticals Inc., AstraZeneca, Pfizer, Bayer HealthCare Pharmaceuticals Inc., Athenex Oncology, Zetagen, Genentech, Artios Pharmaceuticals, Ellipses Pharmaceuticals, Aadi Biopharma, 4D Pharma, Infinity Pharmaceuticals Inc., Eisai, Eli Lilly and Company, Bristol-Myers Squibb, OncoSec, SANOFI US SERVICES INC., Certara, Novartis Pharma, AstraZeneca, Gilead Sciences, Blueprint Medicines Corporation, Reveal Genomics, Eisai, Umoja Biopharmaceuticals, BeyondSpring Pharmaceuticals, Bristol-Myers Squibb, Dana-Farber Cancer Institute, Exelixis Inc. | GC, IC, IC, GC, IC, GC, GC, GC, IC, GC, IC, IC, IC, IC, IC, IC, IC, IC, GC, GC, GC, GC, IC, IC, IC, IC, IC, IC, IC, IC, IC, GC, IC, IC, IC, IC, IC, GC, IC, IC, IC, IC, IC, IC, IC, IC, GC, IC, IC, IC, IC, IC, IC, IC, IC, GC, E, GC | Speaker                    |
| Umoja      | Rukiya     | No Relationships   |   | Staff                      |
| Vellanki   | Paz        | No Relationships   |   | Speaker                    |
| Wethingon  | Stephanie  | AstraZeneca  | E   | Speaker                    |
| Winson     | Kathleen   | Genentech  | E   | Speaker                    |
| Yarchoan   | Mark       | AstraZeneca, Exelixis, Genentech, Replimune, Hepion, Lantus, Bristol-Myers Squibb, Exelixis, Inctye, Genentech, Adevmtris Pharmaceuticals  | IC, IC, IC, IC, GC, GC, GC, GC, OBO   | Speaker                    |

**All of the relevant financial relationships listed for these individuals have been mitigated.**